Nevertheless, large-scale clinical data defining the precise proportion of prostate cancer patients characterized by high FSP1 expression remain unavailable, and robust evidence supporting a direct role of FSP1 in bone metastasis progression or radiotherapy resistance is still lacking [88]. Here, AIFM2 is linked to prostate carcinoma.